Bio-Path Holdings, Inc. (BPTH)
USD 0.15
(0.0%)
USD 0.15
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -939 Thousand USD | 90.76% |
| 2022 | -10.16 Million USD | 56.82% |
| 2021 | -23.53 Million USD | -75.34% |
| 2020 | -13.42 Million USD | 32.91% |
| 2019 | -20.01 Million USD | -1893.13% |
| 2018 | -1 Million USD | 83.17% |
| 2017 | -5.96 Million USD | 36.37% |
| 2016 | -9.37 Million USD | -5.88% |
| 2015 | -8.85 Million USD | 36.11% |
| 2014 | -13.85 Million USD | -290.19% |
| 2013 | -3.55 Million USD | -565.08% |
| 2012 | -534.04 Thousand USD | 43.92% |
| 2011 | -952.25 Thousand USD | -299.16% |
| 2010 | -238.56 Thousand USD | 57.94% |
| 2009 | -567.24 Thousand USD | 62.36% |
| 2008 | -1.5 Million USD | -5536.57% |
| 2007 | 27.72 Thousand USD | -77.75% |
| 2006 | 124.58 Thousand USD | -48.03% |
| 2005 | 239.71 Thousand USD | 29.9% |
| 2004 | 184.53 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.95 Million USD | -3735.92% |
| 2024 Q1 | -103 Thousand USD | 89.03% |
| 2023 Q4 | -939 Thousand USD | 57.53% |
| 2023 Q2 | -3.27 Million USD | 49.88% |
| 2023 FY | -939 Thousand USD | 90.76% |
| 2023 Q1 | -6.53 Million USD | 35.69% |
| 2023 Q3 | -2.21 Million USD | 32.51% |
| 2022 FY | -10.16 Million USD | 56.82% |
| 2022 Q3 | -13.4 Million USD | 20.0% |
| 2022 Q2 | -16.75 Million USD | 20.04% |
| 2022 Q1 | -20.95 Million USD | 10.99% |
| 2022 Q4 | -10.16 Million USD | 24.18% |
| 2021 Q2 | -27.8 Million USD | 8.78% |
| 2021 Q1 | -30.48 Million USD | -127.08% |
| 2021 FY | -23.53 Million USD | -75.34% |
| 2021 Q3 | -26.34 Million USD | 5.28% |
| 2021 Q4 | -23.53 Million USD | 10.64% |
| 2020 Q1 | -17.49 Million USD | 12.56% |
| 2020 Q2 | -14.03 Million USD | 19.77% |
| 2020 Q3 | -11.7 Million USD | 16.61% |
| 2020 Q4 | -13.42 Million USD | -14.68% |
| 2020 FY | -13.42 Million USD | 32.91% |
| 2019 Q1 | -19.16 Million USD | -1808.67% |
| 2019 FY | -20.01 Million USD | -1893.13% |
| 2019 Q4 | -20.01 Million USD | -33.84% |
| 2019 Q3 | -14.95 Million USD | 10.47% |
| 2019 Q2 | -16.69 Million USD | 12.86% |
| 2018 Q3 | -2.28 Million USD | 11.33% |
| 2018 Q2 | -2.57 Million USD | 39.82% |
| 2018 FY | -1 Million USD | 83.17% |
| 2018 Q1 | -4.28 Million USD | 28.18% |
| 2018 Q4 | -1 Million USD | 56.08% |
| 2017 Q2 | -6.18 Million USD | 13.06% |
| 2017 Q1 | -7.11 Million USD | 24.15% |
| 2017 FY | -5.96 Million USD | 36.37% |
| 2017 Q4 | -5.96 Million USD | -29.03% |
| 2017 Q3 | -4.62 Million USD | 25.22% |
| 2016 FY | -9.37 Million USD | -5.88% |
| 2016 Q4 | -9.37 Million USD | 17.03% |
| 2016 Q1 | -6.47 Million USD | 26.9% |
| 2016 Q3 | -11.29 Million USD | -167.5% |
| 2016 Q2 | -4.22 Million USD | 34.74% |
| 2015 Q2 | -11.07 Million USD | 11.03% |
| 2015 Q3 | -9.85 Million USD | 11.06% |
| 2015 Q4 | -8.85 Million USD | 10.15% |
| 2015 FY | -8.85 Million USD | 36.11% |
| 2015 Q1 | -12.45 Million USD | 10.14% |
| 2014 FY | -13.85 Million USD | -290.19% |
| 2014 Q4 | -13.85 Million USD | 5.31% |
| 2014 Q3 | -14.63 Million USD | 6.9% |
| 2014 Q2 | -15.72 Million USD | 6.53% |
| 2014 Q1 | -16.81 Million USD | -373.55% |
| 2013 Q3 | -4.1 Million USD | -112.78% |
| 2013 Q1 | -288.7 Thousand USD | 45.94% |
| 2013 Q2 | -1.92 Million USD | -567.54% |
| 2013 FY | -3.55 Million USD | -565.08% |
| 2013 Q4 | -3.55 Million USD | 13.39% |
| 2012 Q3 | -332.86 Thousand USD | -104.91% |
| 2012 Q1 | -576.82 Thousand USD | 39.43% |
| 2012 Q2 | -162.44 Thousand USD | 71.84% |
| 2012 Q4 | -534.04 Thousand USD | -60.44% |
| 2012 FY | -534.04 Thousand USD | 43.92% |
| 2011 Q2 | -1.22 Million USD | -59.53% |
| 2011 FY | -952.25 Thousand USD | -299.16% |
| 2011 Q4 | -952.25 Thousand USD | 3.16% |
| 2011 Q3 | -983.28 Thousand USD | 19.51% |
| 2011 Q1 | -765.76 Thousand USD | -220.99% |
| 2010 FY | -238.56 Thousand USD | 57.94% |
| 2010 Q1 | -454.57 Thousand USD | 19.86% |
| 2010 Q2 | -602.42 Thousand USD | -32.52% |
| 2010 Q3 | -105.57 Thousand USD | 82.47% |
| 2010 Q4 | -238.56 Thousand USD | -125.96% |
| 2009 Q3 | -265.96 Thousand USD | 48.43% |
| 2009 Q4 | -567.24 Thousand USD | -113.28% |
| 2009 Q2 | -515.74 Thousand USD | 34.14% |
| 2009 Q1 | -783.15 Thousand USD | 48.03% |
| 2009 FY | -567.24 Thousand USD | 62.36% |
| 2008 Q4 | -1.5 Million USD | 15.1% |
| 2008 FY | -1.5 Million USD | -5536.57% |
| 2008 Q1 | -2.5 Million USD | -8303.13% |
| 2008 Q2 | -2.25 Million USD | 10.08% |
| 2008 Q3 | -1.77 Million USD | 21.22% |
| 2007 FY | 27.72 Thousand USD | -77.75% |
| 2007 Q4 | 30.54 Thousand USD | -39.33% |
| 2007 Q2 | 27.72 Thousand USD | -3.11% |
| 2007 Q1 | 28.61 Thousand USD | -81.82% |
| 2007 Q3 | 50.34 Thousand USD | 81.62% |
| 2006 Q1 | 38.85 Thousand USD | -61.26% |
| 2006 Q3 | 136.96 Thousand USD | 9.94% |
| 2006 Q4 | 157.4 Thousand USD | 14.92% |
| 2006 FY | 124.58 Thousand USD | -48.03% |
| 2006 Q2 | 124.58 Thousand USD | 220.64% |
| 2005 Q2 | 239.71 Thousand USD | 0.0% |
| 2005 Q3 | 82.77 Thousand USD | -65.47% |
| 2005 Q4 | 100.29 Thousand USD | 21.16% |
| 2005 FY | 239.71 Thousand USD | 29.9% |
| 2004 FY | 184.53 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 151.704% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 75.387% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 174.88% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 102.915% |
| Better Therapeutics, Inc. | -860 Thousand USD | -9.186% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 96.052% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 385.896% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 120.547% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 83.874% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 129.362% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 129.652% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 118.772% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 100.701% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 624.142% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 107.61% |
| Molecular Templates, Inc. | 707 Thousand USD | 232.815% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 314.166% |
| NexImmune, Inc. | -3.13 Million USD | 70.035% |
| Orgenesis Inc. | 21.78 Million USD | 104.311% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 135.894% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -188454.217% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 80.066% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -653.763% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 100.847% |
| Statera Biopharma, Inc. | 14.41 Million USD | 106.513% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 87.638% |
| Trevena, Inc. | 2.25 Million USD | 141.585% |
| Vaxxinity, Inc. | 10.13 Million USD | 109.268% |
| Vaccinex, Inc. | -1.28 Million USD | 27.096% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 372.612% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 107.093% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 1404.855% |